Mr. Soriot said AstraZeneca would produce more than 100 million doses of its COVID-19 vaccine by the end of February. He also said the drugmaker is aiming for a monthly production goal of 200 million doses by April.
AstraZeneca is also developing new versions of its vaccine that targets newly emerged variants of the novel coronavirus. The drugmaker said during its earnings call that it will start mass production of these modified vaccines within six to nine months.
More articles on pharmacy:
Pharmacy chains on hiring sprees to support COVID-19 vaccination campaign
FDA authorizes new COVID-19 antibody cocktail from Eli Lilly
FDA restricts use of convalescent plasma to hospitalized COVID-19 patients
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
